- The effects of Raloxifene therapy on endometrium in postmenopausal women
-
Kim GJ, Park HM
- KMID: 2272575
- Korean J Obstet Gynecol.
- 2005 Apr;48(4):962-968.
OBJECTIVE: To determine the effects of a selective estrogen receptor modulator (SERM), raloxifene, on endometrium in postmenopausal women. METHODS: Double-blind randomized controlled study was designed for 138 healthy postmenopausal women to... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of New Fractures after Treatment with Alendronate or Raloxifene in Patients with Osteoporotic Compression Fracture Treated with Cement Augmentation
-
Seo JH, Lee KY, Kim KW, Kim HH
- KMID: 2314149
- Osteoporosis.
- 2014 Dec;12(3):117-123.
- doi: 10.0000/ost.2014.12.3.117
BACKGROUNDS: The purpose of this study was to examine the incidence of new fractures after treatment with alendronate or raloxifene in patients with compression fractures treated with cement augmentation. METHODS: 140... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of the Combined Therapy with Raloxifene and Low-Dose Intermittent Fluoride for Two Years in Postmenopausal Women with Osteoporosis
-
Chung SM, Kim GC
- KMID: 2324522
- J Korean Acad Rehabil Med.
- 2007 Apr;31(2):207-212.
OBJECTIVE: To compare the effects of raloxifene alone with a combination of raloxifene and fluoride in postmenopausal osteoporosis on bone mineral density, bone turnover and lipid profiles, at 2 year. METHOD:... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Effects of Alendronate and Raloxifene on Lumbar Bone Mineral Density, Bone Turnover, and Lipid Metabolism in Elderly Women with Osteoporosis
-
Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto
- KMID: 2396095
- Yonsei Med J.
- 2008 Feb;49(1):119-128.
PURPOSE: To compare the effects of alendronate and raloxifene on lumbar bone mineral density (BMD), bone turnover, and lipid metabolism in elderly women with osteoporosis. Subjects and Methods: One hundred... -
- CITED
-
- Close
- SHARE
-
- Close
- Combination Therapy of Raloxifene and Alendronate for Treatment of Osteoporosis in Elderly Women
-
Um MJ, Cho EA, Jung H
- KMID: 2378225
- J Menopausal Med.
- 2017 Apr;23(1):56-62.
- doi: 10.6118/jmm.2017.23.1.56
OBJECTIVES: To evaluate and compare the efficacy and safety of the combination of raloxifene and alendronate with those of monotherapies in elderly women with osteoporosis. METHODS: Sixty-two postmenopausal women (mean age... -
- CITED
-
- Close
- SHARE
-
- Close
- Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist for Severe Endometriosis: Effects on Bone Mineral Density
-
Cho YH, Um MJ, Kim SJ, Kim SA, Jung H
- KMID: 2378238
- J Menopausal Med.
- 2016 Dec;22(3):174-179.
- doi: 10.6118/jmm.2016.22.3.174
OBJECTIVES: To evaluate the efficacy of raloxifene in preventing bone loss associated with long term gonadotropin-releasing hormone agonist (GnRH-a) administration. METHODS: Twenty-two premenopausal women with severe endometriosis were treated with leuprolide... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effects of 3-year Hormone Therapy, Raloxifene and Alendronate on Serum Lipid Profile and Body Mass Index in Postmenopausal Women
-
Kim M, Choi H, Lee JE, Ko J, Lee C, Cho Y, Kim B
- KMID: 2314132
- Osteoporosis.
- 2013 Apr;11(1):33-42.
OBJECTIVES: To evaluate the effects of 3-year hormone therapy, raloxifene and alendronate on lipid profile and body mass index (BMI) in Korean postmenopausal women. METHODS: We studied 107 postmenopausal women who... -
- CITED
-
- Close
- SHARE
-
- Close
- Erratum to: Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist for Severe Endometriosis: Effects on Bone Mineral Density
-
Cho YH, Um MJ, Kim SJ, Kim SA, Jung H
- KMID: 2378229
- J Menopausal Med.
- 2017 Apr;23(1):77-77.
- doi: 10.6118/jmm.2017.23.1.77
The author and author's affiliation should be corrected. -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of 3 Years of Hormone Therapy, Raloxifene, and Alendronate on Mammographic Breast Density in Postmenopausal Korean Women
-
Kim M, Choi H
- KMID: 2201115
- J Korean Soc Menopause.
- 2011 Aug;17(2):94-101.
OBJECTIVES: Breast density is an independent risk factor for the development of invasive breast cancer. We conducted this study to evaluate the effects of 3 years of hormone therapy, raloxifene,... -
- CITED
-
- Close
- SHARE
-
- Close
- Selective Estrogen Receptor Modulators
-
An KC
- KMID: 2349306
- Asian Spine J.
- 2016 Aug;10(4):787-791.
- doi: 10.4184/asj.2016.10.4.787
Selective estrogen receptor modulators (SERMs) are now being used as a treatment for breast cancer, osteoporosis and postmenopausal symptoms, as these drugs have features that can act as an estrogen... -
- CITED
-
- Close
- SHARE
-
- Close
- The Beneficial and Adverse Effects of Raloxifene in Menopausal Women: A Mini Review
-
Khorsand I, Kashef R, Ghazanfarpour M, Mansouri E, Dashti S, Khadivzadeh T
- KMID: 2455892
- J Menopausal Med.
- 2018 Dec;24(3):183-187.
- doi: 10.6118/jmm.2018.24.3.183
OBJECTIVES: The present mini review aimed to summarize the existing knowledge regarding the beneficial and adverse effects of raloxifene in menopausal women. METHODS: This study is a review of relevant publications... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Anti-osteoporotic Medications and Alternatives
-
Kang BM
- KMID: 2272985
- Korean J Obstet Gynecol.
- 2006 Dec;49(12):2459-2472.
Osteoporosis becomes a serious health threat for aging postmenopausal women by predisposing them to an increased risk of fracture. Conventional pharmacological options are available for osteoporosis therapy, including bisphosphonates, the... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Bone Mineral Density of Lumbar Spine in Osteoporotic Patients Treated with Percutaneous Vertebroplasty
-
Kim KH, Lee HJ, Baik SW, Kim HK, Kwon JY, Kim CH
- KMID: 2236695
- Korean J Anesthesiol.
- 2004 Mar;46(3):302-305.
- doi: 10.4097/kjae.2004.46.3.302
BACKGROUND: Osteoporosis and its associated fractures have become increasingly common in Korea because of increasing population age. Both alendronate (ALN) and raloxifene (RLX) can treat and prevent new vertebral fractures.... -
- CITED
-
- Close
- SHARE
-
- Close
- Endocrine Therapy for Breast Cancer
-
Woo J, Lim W
- KMID: 2171288
- Ewha Med J.
- 2014 Sep;37(2):83-91.
- doi: 10.12771/emj.2014.37.2.83
Breast cancer is the second most common cancer in Korean women and its mortality rate has increased steadily. Although breast cancer is heterogeneous tumor, hormone receptor-positive tumors comprise about 75... -
- CITED
-
- Close
- SHARE
-
- Close
- Growth Inhibition of Human Uterine Leiomyoma Cells by Selective Estrogen Receptor Modulator
-
Lee MY, Cho CH, Kwon SH, Song DK, Chung SW, Kang HO, Yoon SD, Cha SD
- KMID: 2272357
- Korean J Obstet Gynecol.
- 2004 Jun;47(6):1071-1079.
OBJECTIVE: Our purpose was to evaluate potential efficacy of selective estrogen receptor modulators (raloxifene and tamoxifen) to human uterine leiomyoma cells. METHODS: The samples were collected from ten hysterectomized specimen. we... -
- CITED
-
- Close
- SHARE
-
- Close
- Medical Treatment of Osteoporosis
-
Byun DW
- KMID: 2183506
- J Korean Med Assoc.
- 2004 Sep;47(9):889-894.
- doi: 10.5124/jkma.2004.47.9.889
Osteoporosis is a common and significant health problem in more than 1/3 of postmenopausal women. Strategies for the medical treatment of osteoporosis are primarily based on decreasing the resorption component... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacologic treatment of osteoporosis
-
Min YK
- KMID: 2358432
- J Korean Med Assoc.
- 2016 Nov;59(11):847-856.
- doi: 10.5124/jkma.2016.59.11.847
The objectives of this article are to review current pharmacologic approaches for the treatment of osteoporosis in Korea. Calcium and vitamin D supplementation are necessary for osteoporotic patients with inadequate... -
- CITED
-
- Close
- SHARE
-
- Close
- Identification of a mutation in the human raloxifene response element of the transforming growth factor-3 gene
-
Han KO, Kang YS, Hwang CS, Moon IG, Yim CH, Chung HY, Jang HC, Yoon HK, Han IK, Choi YK
- KMID: 2157560
- J Korean Med Sci.
- 2001 Oct;16(5):549-552.
- doi: 10.3346/jkms.2001.16.5.549
The human transforming growth factor-3 (TGF-3) is an important cytokine to maintain bone mass by inhibiting osteoclast differentiation. Recently raloxifene response element (RRE), a new enhancer with a polypurine sequence... -
- CITED
-
- Close
- SHARE
-
- Close
- Weight and Bone Mineral Density: The Summary of Epidemiological Evidence
-
Park HA, Kim HJ, Kim TJ, Park JJ, Park JK
- KMID: 2235624
- Korean J Fam Med.
- 2009 Mar;30(3):167-174.
- doi: 10.4082/kjfm.2009.30.3.167
Not only bone mineral density (BMD) is strongly associated with body weight, but also weight change infl uences BMD change. The weight change related bone change is more marked in... -
- CITED
-
- Close
- SHARE
-
- Close
- Oral Bisphosphonate and Risk of Esophageal Cancer: A Nationwide Claim Study
-
Seo GH, Choi HJ
- KMID: 2170091
- J Bone Metab.
- 2015 May;22(2):77-81.
- doi: 10.11005/jbm.2015.22.2.77
BACKGROUND: Epidemiology studies suggest that oral bisphosphonate may increase the risk of esophageal cancer. The present study aimed to investigate the association between exposure of oral bisphosphonate and risk of... -
- CITED
-
- Close
- SHARE
-
- Close
